Showing results (301-310 of 425) with videos related to
Sort By:
Pageof 43
Clinical Immunology (Orlando, Fla.)|July 21, 2018
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial designDoreen O Jackson, Francois A Trappey, G Travis Clifton, et al.Cancer Treatment Reviews|November 21, 2024
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and ImmunotherapyChiara Corti, Busem Binboğa Kurt, Beyza Koca, et al.Annals of Surgery|August 8, 2012
Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trialKelly K Hunt, Karla V Ballman, Linda M McCall, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapyElizabeth A Mittendorf, Jacqueline S Jeruss, Susan L Tucker, et al.Cancer Discovery|June 21, 2019
Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast CancerJaclyn Sceneay, Gregory J Goreczny, Kristin Wilson, et al.Annals of Surgical Oncology|November 9, 2016
Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary TherapyElizabeth FitzSullivan, Roland L Bassett, Henry M Kuerer, et al.Annals of Surgical Oncology|May 25, 2016
Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast CancerJose Vila, Elizabeth A Mittendorf, Gabriel Farante, et al.Cancer Research|May 20, 2016
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular DomainKeith L Knutson, Raphael Clynes, Barath Shreeder, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast CancerG Travis Clifton, Diane Hale, Timothy J Vreeland, et al.Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|May 21, 2021
Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV TrialPuneet Singh, Marion E Scoggins, Aysegul A Sahin, et al.Pageof 43